Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis

作者：Alexander Wu, Arianna Zhang, Yujia Guo, Jialiang Liu, Donghan M. Yang, Lourdes M. Pérez-Chada, Alexis Ogdie, Soumya M. Reddy, Alice B. Gottlieb, José U. Scher, Joseph F. Merola · 发表于：JAMA Dermatology · 年份：2025 · DOI：10.1001/jamadermatol.2025.2980 · 被引用次数：1 · 研究领域：Spondyloarthritis Studies and Treatments、Psoriasis: Treatment and Pathogenesis、Rheumatoid Arthritis Research and Therapies

Importance: Achieving good disease control in psoriatic arthritis (PsA) remains a major challenge. Combining multiple systemic immunomodulatory therapies has been shown to be beneficial in other immune-mediated diseases with reasonable safety profiles, but data on the current use and safety of combination targeted therapy among individuals with PsA are limited. Objective: To evaluate the use and safety of combination targeted therapies among adults with PsA. Design, Setting, and Participants: Data from the IBM MarketScan Commercial Claims Database from January 2015 to December 2024 were used to describe use patterns and perform safety analyses. Data were analyzed from April 2024 to June 2025. A validated claims algorithm was used to identify adults with PsA, who were separated into a standard therapy control cohort that was matched 2:1 with the combination targeted therapy cohort. Main Outcomes and Measures: Descriptive analysis of the use of combination targeted therapies. The safety analysis included a comparison of frequencies of International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes for serious or opportunistic infections requiring an inpatient level of care. Relative risks (RRs) were calculated before and after propensity score matching. Results: Among 82 399 individuals identified with PsA, 542 individuals (median [IQR] age, 52.5 [44.0-59.0] years; 341 female individuals [62.9%]) were receiving combination targete...